Legal
The CMA said some pharmaceutical firms charge the NHS with excessively high prices for hydrocortisone tablets and paid off potential competitors to stay out of the market.
Kevin Mulleady and Jason Aryeh attempted to back a slate of candidates for the Phoenixus Board of Directors but failed as shareholders overwhelmingly supported the current board.
A former CEO of Vyera and other activist investors are pushing a slate of new company directors who would steer control of Phoenixus and Vyera away from Shkreli.
The move by the 15 states’ attorneys general comes about a month ahead of a court hearing set for Aug. 5.
The two were charged with conspiracy to commit trade secret theft and wire fraud, international money laundering and obstruction of justice.
Following a manufacturing mistake that left Emergent BioSolutions with a botched batch of Johnson & Johnson’s COVID-19 vaccine, Emergent is now facing a shareholder lawsuit accusing the company of insider trading.
bluebird bio is hitting back at Spark Therapeutics over the use of the word “spark” involving the company’s “Be the Spark” campaign against sickle cell disease.
The board strongly believes that Walmsley is the correct leader for the pharmaceutical business arm of GSK, which is being referred to as New GSK.
The deal was originally inked in 2005, where U.S.-based Chiron Corp. made payments to Genentech, a Roche company.
Adamis has sent a letter to stockholders urging them to re-elect all the five board members as part of a strategic move to continue and maintain its current growth initiatives.
PRESS RELEASES